Excellent (90 to 100%)
See Additional Information


General Information

  • Lower respiratory tract infections (CAP, HAP)
  • Monitor QTc in patients with increased risk
  • QTc prolongation
  • Dysglycemia
  • Tendon rupture
  • GI intolerance
  • C. difficile colitis
  • Allergic reactions
  • Photosensitivity
  • CNS: headache, malaise, insomnia, restlessness, dizziness, seizure
  • Weakness exacerbation in myasthenia gravis (Avoid use)
  • Retinal detachment
  • Peripheral neuropathy
  • Increased hepatic enzymes
  • Interstitial nephritis
  • Avoid concurrent use with other drugs that prolong the QT interval.
  • Agents with Blood Glucose Lowering Effects - decreased blood sugar control may occur with quinolone use.
  • Cations/Vitamins and minerals - decreased absorption of quinolones (avoid concurrent administration).
  • Corticosteroids (systemic) - increased risk of tendonitis and tendon rupture.
  • NSAIDs - may increase risk of seizure.
  • Sevelamer - may decrease levofloxacin absorption.
  • Tacrolimus (systemic) - may increase the serum concentration of tacrolimus.
  • Warfarin - may increase INR with co-administration.


  • PO: $0.41/Dose; $2.05/5 Days
  • IV: $49.35/Dose; $246.75/5 Days

Antimicrobial class: 2nd Generation/Respiratory Fluoroquinolone

Pregnancy category: C

Average serum half life: 7 hours

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic